2,3'-bipyridine-3-carbonitrile | 870065-12-6

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吡啶及其衍生物
• 英文名称: 2,3'-bipyridine-3-carbonitrile
• 英文别名: [2,3']bipyridinyl-3-carbonitrile；2,3'-bipyridine；2-(Pyridin-3-yl)nicotinonitrile；2-pyridin-3-ylpyridine-3-carbonitrile
• CAS: 870065-12-6
• 化学式: C₁₁H₇N₃
• 分子量: 181.197
• InChiKey: VRDGLLBCHXSRMB-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.2
• 重原子数：
  14
• 可旋转键数：
  1
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.0
• 拓扑面积：
  49.6
• 氢给体数：
  0
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  2,3'-bipyridine-3-carbonitrile 在 氨 、 氢气 作用下， 以 甲醇 为溶剂， 以49 %的产率得到[2,3'-bipyridin]-3-ylmethanamine
  参考文献：
  名称：

  [EN] A CYCLIN-DEPENDENT KINASE INHIBITOR
  [FR] INHIBITEUR DE KINASE DÉPENDANTE DES CYCLINES

  摘要：

  Provided herein are a series of compounds as potent inhibitors of cyclin-dependent kinase (CDK), or pharmaceutically acceptable salts thereof. Corresponding compositions are also provided.

  公开号：

  WO2023046128A1
• 作为产物：
  描述：

  2-氯-3-氰基吡啶 、 3-(1,1,1-三丁基甲锡烷)嘧啶 生成 2,3'-bipyridine-3-carbonitrile
  参考文献：
  名称：

  Amino-tetrazoles analogues and methods of use

  摘要：

  本发明公开了一种具有式(I)或式(II)的化合物，作为P2X7拮抗剂，其中A、B、C、Y、Y、Z、m、v、R1、R2、R3、R4和R5如描述中所定义。还公开了治疗由P2X7调节的疾病或病症的方法和组合物。

  公开号：

  US08546374B2

文献信息

• [EN] ORGANOZINC COMPLEXES AND PROCESSES FOR MAKING AND USING THE SAME<br/>[FR] COMPLEXES D'ORGANOZINC ET PROCÉDÉS POUR LEUR FABRICATION ET LEUR UTILISATION
  申请人：UNIV MUENCHEN L MAXIMILIANS

  公开号：WO2012085168A1

  公开（公告）日：2012-06-28

  Processes for making an organozinc reagents are disclosed comprising reacting (A) organomagnesium or organozinc complexes with (B) at least one coordination compound comprising one or more carboxylate groups and/or alcoholate groups and/or tertiary amine groups, optionally in combination with zinc ions and/or lithium ions and/or halide ions, wherein the halide ions are selected from chloride, bromide and iodide, the organozinc complex comprises an aryl group, a heteroaryl group or a benzyl group when the coordinating compound is a chelating polyamine, and the reaction is conducted in the presence of zinc complexed with at least one coordinating compound when reactant (A) comprises at least one organomagnesium complex. The resulting organozinc reagents may optionally be isolated from solvents to obtain a solid reagent. The reagents may be used for making organic compounds via Negishi cross-coupling reactions or via aldehyde and/or ketone oxidative addition reactions. The organozinc reagents are stable and, due to their high selectivity, permit maintenance of sensitive functional groups such as aldehydes during cross-coupling.

  公开了制备有机锌试剂的方法，包括将（A）有机镁或有机锌配合物与（B）至少一种含有一个或多个羧酸基团和/或醇基团和/或三级胺基团的配位化合物反应，可选地与锌离子和/或锂离子和/或卤离子结合，其中卤离子选自氯离子、溴离子和碘离子，当配位化合物为螯合多胺时，有机锌配合物包括芳基、杂环芳基或苄基，当反应物（A）包含至少一种有机镁配合物时，在存在至少一种配位化合物与锌络合物的情况下进行反应。所得的有机锌试剂可以选择性地从溶剂中分离出来以获得固体试剂。这些试剂可用于通过Negishi交叉偶联反应或通过醛和/或酮氧化加成反应制备有机化合物。有机锌试剂稳定，并且由于其高选择性，允许在交叉偶联过程中保持敏感的官能团，如醛基。
• [EN] AMINO-TETRAZOLES ANALOGUES AND METHODS OF USE<br/>[FR] ANALOGUES D'AMINO-TÉTRAZOLES ET MÉTHODES D'UTILISATION
  申请人：ABBOTT LAB

  公开号：WO2005111003A1

  公开（公告）日：2005-11-24

  A compound having Formula (I) or Formula (II) is disclosed as an P2X7 antagonist, wherein A, B, C, Y, Y, Z, m, v, R1, R2, R3, R4, and R5, are as defined in the description. Methods and compositions for treating disease or condition modulated by P2X7 are also disclosed.

  公开了具有化学式（I）或化学式（II）的化合物作为P2X7拮抗剂，其中A、B、C、Y、Y、Z、m、v、R1、R2、R3、R4和R5如描述中所定义。还公开了用于治疗受P2X7调节的疾病或症状的方法和组合物。
• Preparation of Solid Salt-Stabilized Functionalized Organozinc Compounds and their Application to Cross-Coupling and Carbonyl Addition Reactions
  作者：Sebastian Bernhardt、Georg Manolikakes、Thomas Kunz、Paul Knochel

  DOI：10.1002/anie.201104291

  日期：2011.9.19

  Powdered organozinc reagents: Various aryl and heteroaryl bromides as well as benzylic chlorides react with Mg and Zn(OPiv)2⋅2 LiCl (OPiv=pivalate) to provide solid organozinc reagents after solvent evaporation. These powders can be stored at room temperature under argon for months and can be manipulated in air for a short time. They undergo smooth Negishi cross‐coupling and carbonyl addition reactions

  粉末状有机锌试剂：各种芳基和杂芳基溴化物，以及苄基氯化物与Mg和Zn反应（OPiv）2 ⋅2的LiCl（OPiv =新戊酸盐）溶剂蒸发后，以提供固体有机锌试剂。这些粉末可以在室温下于氩气中保存数月，并可以在空气中短时间操作。它们会进行平稳的Negishi交叉偶联和羰基加成反应（请参见方案）。
• Amino-tetrazole analogues and methods of use
  申请人：Carroll A. William

  公开号：US20060052374A1

  公开（公告）日：2006-03-09

  A compound having Formula (I) or Formula (II) is disclosed as an P2X 7 antagonist, wherein A, B, C, Y, Y, Z, m, v, R 1 , R 2 , R 3 , R 4 , and R 5 , are as defined in the description. Methods and compositions for treating disease or condition modulated by P2X 7 are also disclosed.

  本文披露一种化合物，其化学式为（I）或（II），作为P2X7拮抗剂，其中A、B、C、Y、Y、Z、m、v、R1、R2、R3、R4和R5如描述中所定义。同时，本文还披露了治疗P2X7调节的疾病或病症的方法和组合物。
• Amino-Tetrazoles Analogues and Methods of Use
  申请人：Carroll William A.

  公开号：US20080171733A1

  公开（公告）日：2008-07-17

  A compound having Formula (I) or Formula (II) is disclosed as an P2X 7 antagonist, wherein A, B, C, Y, Y, Z, m, v, R 1 , R 2 , R 3 , R 4 , and R 5 , are as defined in the description. Methods and compositions for treating disease or condition modulated by P2X 7 are also disclosed.

  本发明揭示了一种具有公式（I）或公式（II）的化合物，作为P2X7拮抗剂，其中A，B，C，Y，Y，Z，m，v，R1，R2，R3，R4和R5如描述中所定义。还揭示了用于治疗受P2X7调节的疾病或病况的方法和组合物。